

August 15, 2018

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Norio Hamada, Chairman of the Board and Representative Director, Chief Executive Officer (CEO) (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Public and Investor Relations Department (TEL: 81-3-6838-2803)

## Notice Regarding Marketing Approvals for 2 Ingredients / 3 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director, Chief Executive Officer (CEO): Norio Hamada) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has received approvals for marketing of 2 ingredients / 3 products of generic drugs today on August 15, 2018 as below.

### Products list approved for marketing

Classes	Product Name	Original Brand Name
Therapeutic Agent for Pain	TOARASET Combination Tablets "KYOSOMIRAI"	TRAMCET Combination Tablets
Noradrenergic and Specific Serotonergic Antidepressant (NaSSA)	Mirtazapine Tablets 15mg / 30mg "KYOSOMIRAI"	REMERON / REFLEX Tablets 15mg / 30mg